Drug Discovery - InVivo Biosystems

The Discrepancy Between Sexes: Clinical Models & Clinical Trials

Drug Discovery / By Alexandra Narin / December 28, 2021 December 28, 2021

Pharmaceutical drugs go through a rigorous process that tests their safety and efficacy before gaining FDA approval and being put on the commercial market. Traditionally, preclinical trials utilize mammalian models before clinical trials are performed (mammals are considered the gold standard of trials). But are these trials serving everyone? This article will discuss the pervasive inequality between the male and female sexes in drug development and what can be done about it.

A Closer Look at Nutraceutical Regulations: How Does the USA Compare?

Drug Discovery / By Alexandra Narin / December 17, 2021 December 17, 2021

In this article we will explore how the nutraceutical regulations compare in the USA and abroad, asking how they are defined in each country, what licensing is needed, how this affects manufacturers, and what this indicates for the future of the market.

Recent Nutraceutical Research

Drug Discovery / By Alexandra Narin / December 7, 2021 September 29, 2022

We’ve rounded up some of the recent publications that we’ve been enjoying – click their links below to see what’s new in this space!

Testing the Neuroprotective Effect of a Lead Compound Using C. elegans for Fast and Cost-Effective Answers [Customer Story]

Drug Discovery / By Hannah Huston and Alexandra Narin / November 10, 2021 December 1, 2021

Thanks to InVivo Biosystems, Dr. Galyan now has the data necessary to present to investors to fund additional research into the compound. Additionally, he was able to use the data to submit a patent application on the compound in September of 2021.

FDA versus FTC Approval – What is the Difference?

Drug Discovery / By Alexandra Narin / October 15, 2021 November 30, 2021

In this article we aim to clarify the intent behind these therapies and what their labelling means by asking: Why aren’t nutraceutical products FDA approved? How do FDA and FTC approvals compare? And — how should you market your product? What legal issues do both tracks pose?

HIV, COVID-19, Alzheimer’s: The Impact of The FDA’s Expedited Programs and What’s Next

Drug Discovery / By Alexandra Narin / August 26, 2021 August 26, 2021

The FDA’s emergency use authorization (EUA) of the COVID-19 vaccines has brought the approval process of vaccines and drugs into public consciousness, however, the FDA’s ability to streamline medical products is not new. In this article we will discuss the history of the drug development pipeline, and ways it can be improved.

How Can a Drug Get to Market Faster? Explaining the FDA’s Expedited Drug Tracks

Drug Discovery / By Alexandra Narin / August 17, 2021 August 17, 2021

Getting a drug to market is notoriously difficult, taking 7-10 years and costing hundreds of millions of dollars. This, coupled with the Covid-19 pandemic’s impact on clinical trials, may make you wonder whether your drug is eligible for an expedited track. In this article we will discuss the current ways of expediting drugs, and which is best for your research.

New Alzheimer’s Drug: Helpful or Just Expedient?

Drug Discovery / By Alexandra Narin / August 13, 2021 August 13, 2021

Aducanumab has been plagued with controversy since it was announced. We take a look to see if it is helpful, or just expedient.

Rising Healthcare Costs? Non-Mammalian Models to the Rescue

Disease Modeling, Drug Discovery / By Alexandra Narin / August 11, 2021 August 17, 2021

Rising healthcare costs mean it’s time for pharmaceutical companies to use non-mammalian models in their drug development process — by saving time and money pharmaceutical companies can make a return on their products without sky-high prices for consumers.

The Application of Hypersensitivity Assays to the Discovery of Therapeutics

Disease Modeling, Drug Discovery / By Chris Hopkins / June 14, 2021 June 18, 2021

Using Humanization we can take advantage of the ancient biology between humans and other organisms to create stand-ins – patient avatars – for drug screening studies. In this blog, we will focus on models of inborn errors of metabolism (IEM), as these genetic conditions can lead to hypersensitivity to the metabolite. Since stressor condition hypersensitivity can be used to detect favorable drug effects, IEM model systems are ideal tools for phenotypic screens to find molecules that alleviate the metabolic stress occurring from the deficiency. We discuss the model organisms used in hypersensitivity screens, and why they are advantageous to drug discovery. Ultimately, showcasing this approach’s potential to be widely generalized to many genetic disorders.